Development of an indirect ELISA for screening horses based on the potency of antivenom produced against Iranian Cobra snake

Document Type : Full Research Paper

Author

Department of Venomous Animals and Antivenom, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization (AREEO), Karaj, Iran.

Abstract

In this study, an indirect ELISA test was developed for the determination of the level of antibodies against Cobra venom in equine sera after each injection step. Toxic fractions of Naja naja oxiana snake venom was used as antigen. The test allowed to reveal an increase of antibodies in response to the venom injection and it can be applied to the evaluation of the efficacy of immunization. To the development of the indirect ELISA, dilutions of 1/50, 1/500, and 1/1000 of positive and negative control sera against concentrations of 0.5, 1, and 2 µg/well of the venom were used. From this 2 µg/well of venom and 1:1000 serum dilution was found to be sufficient enough for the estimate of antisnake antibodies. After ELISA development, serums obtained from blood samples of horses immunized with venom were tested to evaluate the trend of increase in antivenom titer at each stage of venom injection. The average optical density of samples after the third injection was 1.213; this is 5.8 times that of the horse samples behind the first step of immunization. All horses had an adequate antivenom titer after the fifth injection. The results suggest that ELISA can be used to determination of antivenom titer in horse sera especially during the initial stages of immunization.
 

Keywords

References

1. Akbari A. H. Rabiei A. Hedayat N. Mohammadpour H. Zolfagharian and S.H. Teymourzadeh. 2010. Production of effective antivenin to treat cobra snake (Naja naja oxiana) envenoming. Archives Razi Institute 65: 33-37.
2. Chippaux J.P. 2011. Estimate of the burden of snakebites in sub-Saharan Africa: a meta-analytic approach. Toxicon 57: 586–599. 
3. Golchinfar F. R. Madani T. Emami H. Zoulfagharian A. Zare and N. Mouhammadpour. 2016. Designing a competitive ELISA for evaluation of anti-snake venom serum potency. Veterinary Researches and Biological Products 29: 9-16.
4. Gutiérrez J.M.  M. Vargas  Á. Segura M. Herrera M. Villalta G. Solano A. Sánchez  C. Herrera and G. León. 2021. In Vitro Tests for Assessing the Neutralizing Ability of Snake Antivenoms: Toward the 3Rs Principles. Frontiers in Immunolgy 11: 617429.
5. Gutierrez J.M. G. Rojas and L. Cerdas. 1987. Ability of polyvalent antivenom to neutralize the venom of Lachesis muta melanocephala. A new Costa Rican subspecies of the bushmaster. Toxicon 25: 713-720.
6. Gutierrez J.M. D. Williams H.W. Fan and D.A. Warrell. 2010. Snakebite envenoming from a global perspective: Towards an integrated approach. Toxicon 56: 1223–1235.
7. Harrison R.A. D.A. Cook C. Renjifo N.R. Casewell R.B. Currier and S.C. Wagstaff. 2011. Research strategies to improve snakebite treatment: challenges and progress. Journal of Proteomics 74: 1768–1780. 
8. Harrison R.A. A. Hargreaves S.C. Wagstaff B. Faragher and D.G. Lalloo. 2009. Snake envenoming: a disease of poverty. PLoS Neglected Tropical Diseases 3: e569. 
9. Hendriksen C.F. 2002. Refinement, reduction, and replacement of animal use for regulatory testing: current best scientific practices for the evaluation of safety and potency of biologicals. ILAR Journal 43: S43-S48.
10. Heneine L.D.G. A.D. Carvalho C.F. Barbosa and M.R.A. Dos Santos. 1998. Development of an ELISA to assess the potency of horse therapeutic polyvalent antibothropic antivenom. Toxicon 36: 1363-1370. 
11. Kasturiratne A. A.R. Wickremasinghe N. de Silva N.K. Gunawardena A. Pathmeswaran R. Premaratna L. Savioli, D.G. Lalloo and H.J. de Silva. 2008.  The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Medicine 5: e218. 
12. Khaing E.M. P.R. Hurtado E. Hurtado A. Zaw J. White D.A. Warrell S. Alfred M.A. Mahmood and C.A. Peh. 2018. Development of an ELISA assay to determine neutralising capacity of horse serum following immunisation with Daboia siamensis venom in Myanmar.  Toxicon 151: 163-168.
13. Kumar B.K. S.S. Nanda P. Venkateshwarlu Y.K. Kumar and R.T. Jadhav. 2010.  Antisnake venom serum (ASVS). International Journal of Pharmacy and Biological Sciences 1:76-89.
14. Kumar S. S. Kumar Y. Behl and R.K. Gupta. 2014. Development and standardization of ELISA as pre-screen test for the potency estimation during commercial production of antisnake venom serum (ASVS). American Journal of Biomedical Sciences 6: 20-31.
15. Laemmli U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685. 
16. Lowry O.H. N.J. Rosbrough A.L. Farr and R.J. Randall. 1951. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193: 265-275.
17. Theakston R.D.G. 1983. The application of immunoassay techniques, including ELISA, to snake venom research. Toxicon 21: 341-352.  
18. WHO. 2010. Guidelines for the production control and regulation of snake antivenom immunoglobulins.
19. WHO. 1981. Progress in the characterization of venoms and standardization of antivenoms. 
20. WHO. 1980. WHO coordination meeting on venoms and antivenoms. 
21. Williams D.J. J.M. Gutierrez J.J. Calvete W. Wuster K. Ratanabanangkoon O. Paiva N.I. Brown N.R. Casewell R.A. Harrison P.D. Rowley M. O'Shea S.D. Jensen K.D. Winkel and D.A. Warrell. 2011. Ending the drought: new strategies for improving the flow of affordable, effective antivenoms in Asia and Africa. Journal of Proteomics 74: 1735–1767.
 

Files

History

  • Receive Date: 09 June 2021
  • Revise Date: 20 August 2021
  • Accept Date: 30 August 2021

Share

How to cite

Statistics